L-tryptophan-kynurenim pathway enzymes are a therapeutic target for various neurological disorders

Research output: Contribution to journalReview article

Abstract

Changes in L-Tryptophan (TRP)-kynurenine (KYN) pathway metabolism play an important role (s) in various neurological disorders such as depressive symptoms associated with cytokine therapy. Indoleamine 2, 3-dioxygenase (IDO) 1 is the rate-limiting and the inflammatory cytokine inducible enzyme of the TRP-KYN pathway and plays a role in immune regulation. Here, the physiological significance of TRP-Kyn pathway metabolism in CNS is summarized. About 90% of total plasma L-TRP is bound to albumin, forming a complex that cannot cross the blood-brain barrier (BBB), but free form L-TRP is available for transport across the BBB into the brain. An important interface exists with the CNS since L-TRP, KYN and 3-hydroxykinurenine (3-HK) can cross the BBB quite readily. On the other hand, QUIN, KYNA and 3-hydroxyanthranilic acid (3-HAA) do not cross the BBB, but their concentrations are elevated markedly after systemic administration of KYN. The altered TRP/KYN ratio in the blood can produce significant secondary changes in the amount of KYNs in the CNS, contributing no doubt to the effects of immune activity and stress. This relationship may be of special significance for understanding the cognitive and neurodegenerative effects of inflammatory CNS diseases. The manipulation of TRP-KYN pathway metabolism through the administration of an enzyme modulator can serve as a novel therapeutic strategy for various neurological disorders.

Original languageEnglish
Pages (from-to)103-107
Number of pages5
JournalJapanese Journal of Neuropsychopharmacology
Volume37
Issue number4
Publication statusPublished - 01-08-2017

Fingerprint

Nervous System Diseases
Kynurenine
Tryptophan
Enzymes
Blood-Brain Barrier
Therapeutics
3-Hydroxyanthranilic Acid
Indoleamine-Pyrrole 2,3,-Dioxygenase
Cytokines
Central Nervous System Diseases
Albumins
Depression
Brain

All Science Journal Classification (ASJC) codes

  • Clinical Psychology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

@article{5ad10c7fbf024526849d7d660b43582b,
title = "L-tryptophan-kynurenim pathway enzymes are a therapeutic target for various neurological disorders",
abstract = "Changes in L-Tryptophan (TRP)-kynurenine (KYN) pathway metabolism play an important role (s) in various neurological disorders such as depressive symptoms associated with cytokine therapy. Indoleamine 2, 3-dioxygenase (IDO) 1 is the rate-limiting and the inflammatory cytokine inducible enzyme of the TRP-KYN pathway and plays a role in immune regulation. Here, the physiological significance of TRP-Kyn pathway metabolism in CNS is summarized. About 90{\%} of total plasma L-TRP is bound to albumin, forming a complex that cannot cross the blood-brain barrier (BBB), but free form L-TRP is available for transport across the BBB into the brain. An important interface exists with the CNS since L-TRP, KYN and 3-hydroxykinurenine (3-HK) can cross the BBB quite readily. On the other hand, QUIN, KYNA and 3-hydroxyanthranilic acid (3-HAA) do not cross the BBB, but their concentrations are elevated markedly after systemic administration of KYN. The altered TRP/KYN ratio in the blood can produce significant secondary changes in the amount of KYNs in the CNS, contributing no doubt to the effects of immune activity and stress. This relationship may be of special significance for understanding the cognitive and neurodegenerative effects of inflammatory CNS diseases. The manipulation of TRP-KYN pathway metabolism through the administration of an enzyme modulator can serve as a novel therapeutic strategy for various neurological disorders.",
author = "Kuniaki Saito",
year = "2017",
month = "8",
day = "1",
language = "English",
volume = "37",
pages = "103--107",
journal = "Japanese Journal of Psychopharmacology",
issn = "1343-4144",
publisher = "Japanese Society of Neuropsychopharmacology",
number = "4",

}

L-tryptophan-kynurenim pathway enzymes are a therapeutic target for various neurological disorders. / Saito, Kuniaki.

In: Japanese Journal of Neuropsychopharmacology, Vol. 37, No. 4, 01.08.2017, p. 103-107.

Research output: Contribution to journalReview article

TY - JOUR

T1 - L-tryptophan-kynurenim pathway enzymes are a therapeutic target for various neurological disorders

AU - Saito, Kuniaki

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Changes in L-Tryptophan (TRP)-kynurenine (KYN) pathway metabolism play an important role (s) in various neurological disorders such as depressive symptoms associated with cytokine therapy. Indoleamine 2, 3-dioxygenase (IDO) 1 is the rate-limiting and the inflammatory cytokine inducible enzyme of the TRP-KYN pathway and plays a role in immune regulation. Here, the physiological significance of TRP-Kyn pathway metabolism in CNS is summarized. About 90% of total plasma L-TRP is bound to albumin, forming a complex that cannot cross the blood-brain barrier (BBB), but free form L-TRP is available for transport across the BBB into the brain. An important interface exists with the CNS since L-TRP, KYN and 3-hydroxykinurenine (3-HK) can cross the BBB quite readily. On the other hand, QUIN, KYNA and 3-hydroxyanthranilic acid (3-HAA) do not cross the BBB, but their concentrations are elevated markedly after systemic administration of KYN. The altered TRP/KYN ratio in the blood can produce significant secondary changes in the amount of KYNs in the CNS, contributing no doubt to the effects of immune activity and stress. This relationship may be of special significance for understanding the cognitive and neurodegenerative effects of inflammatory CNS diseases. The manipulation of TRP-KYN pathway metabolism through the administration of an enzyme modulator can serve as a novel therapeutic strategy for various neurological disorders.

AB - Changes in L-Tryptophan (TRP)-kynurenine (KYN) pathway metabolism play an important role (s) in various neurological disorders such as depressive symptoms associated with cytokine therapy. Indoleamine 2, 3-dioxygenase (IDO) 1 is the rate-limiting and the inflammatory cytokine inducible enzyme of the TRP-KYN pathway and plays a role in immune regulation. Here, the physiological significance of TRP-Kyn pathway metabolism in CNS is summarized. About 90% of total plasma L-TRP is bound to albumin, forming a complex that cannot cross the blood-brain barrier (BBB), but free form L-TRP is available for transport across the BBB into the brain. An important interface exists with the CNS since L-TRP, KYN and 3-hydroxykinurenine (3-HK) can cross the BBB quite readily. On the other hand, QUIN, KYNA and 3-hydroxyanthranilic acid (3-HAA) do not cross the BBB, but their concentrations are elevated markedly after systemic administration of KYN. The altered TRP/KYN ratio in the blood can produce significant secondary changes in the amount of KYNs in the CNS, contributing no doubt to the effects of immune activity and stress. This relationship may be of special significance for understanding the cognitive and neurodegenerative effects of inflammatory CNS diseases. The manipulation of TRP-KYN pathway metabolism through the administration of an enzyme modulator can serve as a novel therapeutic strategy for various neurological disorders.

UR - http://www.scopus.com/inward/record.url?scp=85032697089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032697089&partnerID=8YFLogxK

M3 - Review article

VL - 37

SP - 103

EP - 107

JO - Japanese Journal of Psychopharmacology

JF - Japanese Journal of Psychopharmacology

SN - 1343-4144

IS - 4

ER -